JPRN-UMIN000007482
Completed
未知
ow dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy - Low dose of Intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy
Division of Ophthalmology, Department of Visual Sciences, Surugadai-Hospital, Nihon University.0 sites60 target enrollmentApril 1, 2012
ConditionsProliferative diabetic retinopathy
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Proliferative diabetic retinopathy
- Sponsor
- Division of Ophthalmology, Department of Visual Sciences, Surugadai-Hospital, Nihon University.
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who had undergone intraocular surgery or retinal photocoagulation within 6 months before the study, and those who had undergone intravitreal injection of drugs or sub\-Tenon injection of steroids within 6 months before the study were excluded.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Intravitreal Bevacizumab (Avastin) therapy for Proliferative Diabetic Retinopathydiabetic retinopathy.Retinal disorders in diseases classified elsewhereIRCT138903314232N1Vice chancellor for research; Babol university of medical sciences39
Active, not recruiting
Not Applicable
Intravitreal Bevacizumab Avastin, Roche, United Kingdom for exudative maculopathies - Intravitreal bevacizumabEUCTR2005-006182-14-ITIVERSITA DEGLI STUDI DI UDINE30
Recruiting
Not Applicable
Evaluation of vitamin D effect on diabetic macular edemadiabetic macular edema.Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edemaE08.311IRCT20200407046978N1Shahid Beheshti University of Medical Sciences60
Active, not recruiting
Not Applicable
se of subconjunctival Bevacizumab (Avastin) in treatment of corneal neovascularization non curable with standard protocols (topical and sistemic steroids). - NDCorneal neovascularizationMedDRA version: 9.1Level: LLTClassification code 10055665Term: Corneal neovascularisationEUCTR2007-007787-25-ITAZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
Completed
Phase 2
Bevacizumab treatment of intra-venous administration and diagnostic nuclear medicine for symptomatic radiation necrosis in the braiJPRN-UMIN000005391Department of Neurosurgery, Osaka Medical College40